AKBA - Akebia Therapeutics, Inc.
4.5200 0.00 (0.00%)
After hours: 5:07PM EDT
| Previous Close | 4.6100 |
| Open | 4.5800 |
| Bid | 4.1700 x 2200 |
| Ask | 4.5200 x 4000 |
| Day's Range | 4.4300 - 4.7200 |
| 52 Week Range | 3.5000 - 10.4500 |
| Volume | 450,114 |
| Avg. Volume | 990,685 |
| Market Cap | 537.265M |
| Beta (3Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3950 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.48 |
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT
Q2 2019 Akebia Therapeutics Inc Earnings Call
- Business Wire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 277,250 shares of Akebia’s common stock on August 30, 2019, including an option to purchase 250,000 shares granted to Steven K. Burke, M.D., Akebia’s newly-hired Senior Vice President, Chief Medical Officer. The options were granted as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $4.13 per share, which is equal to the closing price of Akebia’s common stock on the grant date.
- American City Business Journals
In expense-laden biotech industry, here are the Mass. startups most in need of cash
Unlike commercial-stage companies that have product revenues, drug startups largely rely on private equity funding, stock sales and debt financing to fund their operations. And those operations can be pricey.
- Simply Wall St.
How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?
If you own shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) then it's worth thinking about how it contributes to the...
Motley FoolAkebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript
AKBA earnings call for the period ending June 30, 2019.
- Business Wire
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P.
- Zacks
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights
CAMBRIDGE, Mass.-- -- Auryxia ® Revenue Increases to $29.1 Million for Q2’FY19, Up 21% from Q2’FY18 and Up 26% from Q1’FY19; ANDA Settlement Reinforces Strength of Auryxia IP; and, Vadadustat Achieves Key Regulatory Milestone with JNDA Submission Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, ...
- Business Wire
Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical
Akebia Therapeutics, Inc. (AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and License Agreement (Agreement) with Par Pharmaceutical, Inc., an Endo International company (Par). This settlement resolves patent litigation brought by Keryx and Panion in response to Par’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Auryxia (ferric citrate) tablets prior to the expiration of the applicable patents.
- Zacks
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s (NASDAQ:AKBA)?
The big shareholder groups in Akebia Therapeutics, Inc. (NASDAQ:AKBA) have power over the company. Institutions often...
- Simply Wall St.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
- Insider Monkey
Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT
Q1 2019 Akebia Therapeutics Inc Earnings Call
- Business Wire
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
Motley FoolAkebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript
AKBA earnings call for the period ending March 31, 2019.
- Insider Monkey
Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
